Teva Pharmaceutical Industries (TEVA) Operating Expenses (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Operating Expenses came in at $1.3 billion in Q2 2026, up 34.2% YoY from $959.0 million in Q2 2025, and up 28.7% on a QoQ basis from $1.0 billion in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Operating Expenses (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Operating Expenses data on file, last reported at $1.3 billion in Q2 2026.
- Quarterly Operating Expenses rose 34.2% year-over-year to $1.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $4.4 billion (up 16.68% YoY) and the FY2025 annual result came in at $4.0 billion, up 7.32% from the prior year.
- Operating Expenses climbed to $1.3 billion in Q2 2026, from $1.0 billion in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $1.3 billion in Q2 2026 to a low of $822.0 million in Q3 2022.
- A 5-year average of $939.1 million and a median of $914.5 million in 2023 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses declined 7.82% — and 2026, when it surged 34.2%.
- Tracing TEVA's Operating Expenses over 5 years: stood at $837.0 million in 2022, then increased by 7.77% to $902.0 million in 2023, then gained by 5.54% to $952.0 million in 2024, then increased by 17.65% to $1.1 billion in 2025, then rose by 14.91% to $1.3 billion in 2026.
- The last three Operating Expenses figures came in at $1.3 billion (Q2 2026), $1.0 billion (Q1 2026), and $1.1 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.87 Bn | 42.91 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.64 Bn | 2.15 Bn | 1.29 Bn |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn | 215.00 Mn |
| 4 | Takeda Pharmaceutical | 28.74 Bn | 22.95 Bn | 5.10 Bn | -2.85 Bn |
| 5 | United Therapeutics | 22.26 Bn | 19.60 Bn | 683.80 Mn | 452.50 Mn |
| 6 | Viatris | 18.85 Bn | 17.96 Bn | 1.46 Bn | 1.45 Bn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 807.50 Mn |
| 8 | Elanco Animal Health | 12.15 Bn | 11.62 Bn | 798.00 Mn | 550.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.28 Bn | 7.62 Bn | 397.90 Mn | 477.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.29 Bn |
| Mar 31, 2026 | 1.00 Bn |
| Dec 31, 2025 | 1.12 Bn |
| Sep 30, 2025 | 973.00 Mn |
| Jun 30, 2025 | 959.00 Mn |
| Mar 31, 2025 | 919.00 Mn |
| Dec 31, 2024 | 952.00 Mn |
| Sep 30, 2024 | 924.00 Mn |
| Jun 30, 2024 | 939.00 Mn |
| Mar 31, 2024 | 886.00 Mn |
| Dec 31, 2023 | 902.00 Mn |
| Sep 30, 2023 | 844.00 Mn |
| Jun 30, 2023 | 910.00 Mn |
| Mar 31, 2023 | 842.00 Mn |
| Dec 31, 2022 | 837.00 Mn |
| Sep 30, 2022 | 822.00 Mn |
| Jun 30, 2022 | 907.00 Mn |
| Mar 31, 2022 | 880.00 Mn |
| Dec 31, 2021 | 908.00 Mn |
| Sep 30, 2021 | 888.00 Mn |